Trial Profile
Phase I/II clinical trial of bortezomib (velcade) + pemetrexed (alimta) in previously treated patients with advanced non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jan 2010
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Mar 2008 New trial centre (Trinitas Comprehensive Cancer Center) added according to ClinicalTrials.gov
- 08 Mar 2008 New trial centres added.